An observational study in Covid19, SARS-CoV2 Infection and Olfactory Disorder, sponsored by Association "Naso Sano" Onlus. Status unknown at 1 site in Italy. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-14.
Sponsored by Association "Naso Sano" Onlus · Observational
There are very few long-term studies that analyze the immune responses in patients recovered from COVID-19 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
The main aim of this study is to analyze the clinical profile and immune responses of recovered COVID-19 patients in a representative cohort of people in the Umbria region of Italy. The participants had a history of testing positive for SARS-CoV-2 in March 2020 by Reverse Transcriptase- Quantitative Polymerase Chain Reaction (RT-qPCR). The participants were invited for voluntary participation in a seroprevalence study. This study analyzes longitudinally the presence of antibodies against SARS-CoV-2 by sequential serological tests at different time points using two FDA-approved Immunoassays. At the first serum sample collection, the participants were asked to provide information about their COVID-19 clinical history including clinical profile, co-morbidities, and treatment undertaken using a standardized questionnaire. Successive sequential serological assessments were conducted to understand the immune responses in these recovered patients.
Moreover, stage two of the study involves, analysis of antibody titers in recovered vaccinated individuals and their follow-up.
Study design: A monocentric pilot longitudinal observational study
Study subjects: patients recovered from SARS-CoV-2 infection in March 2020 (detected by RT-PCR)
Study method: The study was conducted after written informed consent for voluntary participation. The antibody titers were longitudinally analyzed by sequential serological tests at different time points (TPs) using two FDA-approved Immunoassays. At the first serum sample collection, the participants were asked to provide information about their COVID-19 clinical history including clinical profile, co-morbidities, and the treatment undertaken using a standardized questionnaire.
From May 2020 to January 2021:
Anti-Nucleocapsid (NCP) antibodies were analyzed using FDA-approved CLIA immunoassay through sequential serum samples.
Time was treated as a factor and six different time points (TPs) were defined (T0-T5). The first blood sample was collected in the month of May 2020, 2 months after the month of infection (March), and was defined as T0. Consecutive serological samples were analyzed at different TPs; three months (T1), five months (T2), seven months (T3), eight months (T4), and ten months (T5) post-infection in June, August, October, November of 2020 and January 2021 respectively.
At this point, a more specific immunoassay was adopted to detect neutralizing antibodies against the Spike-Receptor binding domain for future assessments.
From late February 2021:
an additional n=12 patients (8 female and 4 male), who met the eligibility criteria for participation, were enrolled in the study and added to the original cohort (n=30). These patients (n=12), similar to the original cohort, had a history of testing positive for SARS-CoV-2 by RT-qPCR in March 2020, updating the sample size to n=42.
Since the legal provisions adopted by the Italian Ministry of Health advised mandatory vaccination for all Healthcare Workers, irrespective of previous disease status, n=10 patients (4 female and 6 male) were gradually vaccinated from mid-March 2021 and hence excluded from the original cohort, making the revised final sample size as n=32.
The presence of antibodies was analyzed The study continues to actively enroll patients for future analysis.
with vaccination in progress, the antibody titers of the recovered and then vaccinated patients will also be analysed separately.
7,990 studies on the registry are indexed under COVID-19; 466 are open to participants now.
This study's planned enrollment of 100 is below the median of 268 across 3,208 observational studies indexed under COVID-19.
Browse COVID-19 studies →This is the only study on the registry with Association "Naso Sano" Onlus as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Individuals who tested positive for SARS-CoV-2 in March 2020 and are not vaccinated till date, within the age range of 18-80 years, with no active respiratory infection / active COVID-19 infection and willing to give informed consent were invited to take part in the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
As per the WHO guidelines, the patients were divided into two groups based on disease severity: Mild and Moderately severe. This was based on the self-reported symptoms experienced by the patients during the infection period (March 2020). Intervention: COVID-19 Antibody testing at different time points
Diagnostic Test: COVID-19 antibody test
As per the WHO guidelines, the patients were divided into two groups based on disease severity: Mild and Moderately severe. This was based on the self-reported symptoms experienced by the patients during the infection period (March 2020). Intervention: COVID-19 Antibody testing at different time points
Diagnostic Test: COVID-19 antibody test
FDA-approved Immunoassays were used in the study. At the beginning of the study, up to 3 months, ELISA and CLIA immunoassays were adopted to analyze the antibody titers. Thereafter, CLIA was used for longitudinal analysis of antibody titers for consecutive months. Anti
Analysis of demographic profile (Age) of recovered COVID-19 patients [at inclusion]
Demographic profile included Age at presentation (in years)
Time frame: At inclusion
Analysis of demographic profile (Gender) of recovered COVID-19 patients [at inclusion]
Demographic profile included Sex (gender) at presentation (male/female/other)
Time frame: At inclusion
Analysis of demographic profile (occupation) of recovered COVID-19 patients [at inclusion]
Demographic profile included occupation at presentation (healthcare-worker/non-healthcare)
Time frame: At inclusion
Analysis of clinical profile of recovered COVID-19 patients [at inclusion]
Clinical profile included clinical symptoms experienced at the time of presentation. The participant completed a questionnaire with "Yes" or "no" for each symptom. The symptoms were namely: Fever, Rhinorrhea, Dry cough, Sore throat, Shortness of breath, fatigue, Headche, Muscle ache, skin eruptions, diarrhoea, conjunctivitis, loss of smell, loss of taste, chest pain or any other symptom (please specify).
Time frame: At inclusion
Analysis of associated co-morbidities in recovered COVID-19 patients [at inclusion]
Participants completed a questionnaire with "Yes" or "no" for history of comorbidities namely: Asthma/seasonal allergies, Diabetes Mellitus, Hypertension, cardiovascular disease or any other co-morbidity (please specify).
Time frame: At inclusion
Analysis of immunological profile recovered COVID-19 patients [at inclusion]
The participants were questioned about their respective blood groups.
Time frame: At inclusion
Seroprevalence of IgM and IgG against Nucleocapsid of SARS-CoV-2 (in AU/ml) [from T0 to T5]
From May 2020 to January 2021, anti-nucleocapsid (NCP) antibodies developed against SARS-CoV-2 were analysed using n-CoV IgM/IgG CLIA assay through sequential serological tests in n=30 patients. Time was treated as a factor and six time points were defined. The first blood sample was collected in May 2020 (2 months after infection) and was defined as T0. Consecutive samples were analysed at 3 months (T1), five months (T2) , seven months (T3) and eight months (T4) and ten months (T5) post infection in June, August, October, November of 2020 and January 2021 respectively.
Time frame: 8 months
Seroprevalence of IgM and IgG against spike-receptor binding domain of SARS-CoV-2 (in AU/ml) [from T6 to T8]
A more specific immunoassay (CLIA) against SARS-CoV-2 S-RBD was adopted for future assessments. From late February 2021, an additional n = 12 patients (8 female and 4 male), who met the eligibility criteria for participation, were enrolled in the study and added to the original cohort (n = 30). These patients (n=12), similar to the original cohort, had a history of testing positive for SARS-CoV-2 by RT-qPCR in March 2020, updating the sample size to n = 42. Since the legal provisions adopted by the Italian Ministry of Health advised mandatory vaccination for all Healthcare Workers, irrespective of previous disease status,n=10 patients (4 female, 6 male) were gradually vaccinated from mid-March 2021 and excluded from the original cohort, making the revised final sample size,n = 32.
Time frame: through study completion, an average of 2 years
Seroprevalence of IgM and IgG against spike-receptor binding domain of SARS-CoV-2 (in AU/ml) for vaccinated individuals
The vaccinated recovered individuals continued to report for follow-up for antibody analysis
Time frame: through study completion, an average of 2 years
Co-relation of demographic profile with antibody titers against NCP of SARS-CoV-2 with respect to disease severity [ Time Frame: at inclusion and within observational period ]
Demographic profile such as Age, Sex, occupation were analysed to look for any association with disease severity and antibody titers against NCP at different time points from (T0-T5)
Time frame: 8 months
Co-relation of demographic profile with antibody titers against spike- RBD of SARS-CoV-2 with respect to disease severity [ Time Frame: at inclusion and within observational period ]
Demographic profile such as Age, Sex, occupation were analysed to look for any association with disease severity and antibody titers against spike-RBD at different time points from (T6-T8)
Time frame: 4 months
Co-relation of symptoms and antibody titer levels against Nucleocapsid of SARS-CoV-2 with respect to disease severity [ Time Frame: at inclusion and within observational period ]
Presence of symptoms (in March 2020) suggestive of a common cold, influenza and similar upper respiratory tract infections with help of questionnaire. Symptoms recorded : Fever , Rhinorrea, Dry cough, sore throat, Shortness of breath, Headache, skin eruptions, muscle ache, diarrhoea, conjunctivitis, loss of smell, loss of taste, chest pain and its association with disease severity and antibody titers against NCP at different time points (T0-T5).
Time frame: at inclusion and within the observational period (8 months)
Co-relation of self reported symptoms and antibody titer levels against spike-RBD with respect to disease severity [ Time Frame: at inclusion and within observational period ]
Presence of symptoms (in March 2020) suggestive of a common cold, influenza and similar upper respiratory tract infections with help of questionnaire. Symptoms recorded : Fever , Rhinorrea, Dry cough, sore throat, Shortness of breath, Headache, skin eruptions, muscle ache, diarrhoea, conjunctivitis, loss of smell, loss of taste, chest pain and its association with antibody titers against spike receptor binding domain with respect to disease severity at different time points (T6-T8).
Time frame: at inclusion and within the observational period (4 months)
Co-relation of co-morbidities and antibody titer levels with respect to disease severity [ at inclusion]
history of asthma/ allergies/diabetes/hypertension/cardiovascular diseases and its association with disease severity and anti-NCP antibody titers (quantitative) at different time points (T0-T5)
Time frame: at inclusion and within the observational period (8 months)
Co-relation of co-morbidities and antibody titer levels with respect to disease severity [ at inclusion]
history of asthma/ allergies/diabetes/hypertension/cardiovascular diseases and its association with disease severity and anti-S-RBD antibody titers (quantitative) at different time points (T6-T8)
Time frame: at inclusion and within the observational period (through study completion, an average of 2 years)
Co-relation of antibody titer levels and smell and taste dysfuntion with respect to disease severity [ at inclusion]
history of asthma/ allergies/diabetes/hypertension/cardiovascular diseases and its association with disease severity and anti-S-RBD antibody titers (quantitative) at different time points (T6-T8)
Time frame: at inclusion and within the observational period (through study completion, an average of 2 years)
Plan to share: Undecided — Sensitive clinical data from the patients will be collected. Therefore, it is not yet decided, if it will be possible to share IPD while preserving participant anonymity and privacy.
Started May 2020 (actual). Primary completion is estimated for Nov 2023, 42 months after the start.
Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 42 months is above that.
Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.